EUVIMEDEUVIMED entdecken
Multizentrische Studie

When to Switch to Subcutaneous Infliximab? The RE-WATCH Multicenter Study

Lorenzo Bertani iD, Davide Giuseppe Ribaldone, Fabrizio Bossa, Maria Guerra, Monica Annese, Raffaele Manta, Angelo Armandi, Gian Paolo Caviglia, Alessia Todeschini iD, Angela Variola

Inflammatory Bowel Diseases · 01.12.2025 · 31 (12) · 3363-3369

DOI: 10.1093/ibd/izaf172 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Inflammatory Bowel Diseases, online erschienen am 07.09.2025. Verfasst von Lorenzo Bertani und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Tuscany North-West ASL, Pontedera Hospital, Pontedera, Italy. Hauptthemen laut MEDLINE: Infliximab, Gastrointestinal Agents, Drug Substitution, Antibodies, Monoclonal. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 24 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The infliximab (IFX) biosimilar, CT-P13, is available as an intravenous (IV) and subcutaneous (SC) formulation. Although current indications allow the transition from IV CT-P13 to SC CT-P13 after two IV administrations, some clinicians prefer to postpone switching until stable clinical remission has been achieved.

Methods

We evaluate the endoscopic response, treatment persistence, clinical remission, endoscopic remission, and safety profile after one year of treatment with IFX in patients switched from IV to SC after 6 weeks (early switch group) or after 6 months (late switch group).

Results

There were no statistical differences between the two groups after one year in terms of endoscopic response (71.4% vs 70.8%, P = .95), steroid-free clinical remission (62.5% vs 68.7%, P = .51), or IFX retention rate (75.0% vs 66.7%, P = .35). We observed higher endoscopic remission rates in early switch patients as compared to late switch patients; however, this trend was not significant (69.6% vs 52.1%, P = .07). A return to IV-IFX was required in 1 of 43 early switch patients and in 3 of 44 late switch patients (2.3% vs 6.8%, P = .31). Clinical indexes, fecal calprotectin and C-reactive protein (CRP) levels significantly decreased after one year regardless of group. Adverse events were also comparable between groups (4.5% vs 8.3%, P = .46).

Conclusions

Our study has shown that early switch from IV-IFX to SC-IFX at 6 weeks is effective in terms of clinical and endoscopic remission at one year yielding similar results to late switch at 6 months.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

InfliximabGastrointestinal AgentsDrug SubstitutionAntibodies, MonoclonalBiosimilar PharmaceuticalsColitis, UlcerativeCrohn DiseaseHumansFemaleMaleAdultInjections, SubcutaneousRemission InductionMiddle AgedTreatment OutcomeFollow-Up Studies

Stichwörter der Autor:innen

infliximabsubcutaneousswitchtiming

Substanzen

InfliximabGastrointestinal AgentsCT-P13Antibodies, MonoclonalBiosimilar Pharmaceuticals

Autor:innen und Institutionen

  • Department of Internal Medicine, Tuscany North-West ASL, Pontedera Hospital, Pontedera, Italy.
  • Unit of Gastroenterology, Department of Medical Sciences, University of Turin, Turin, Italy.
  • Unit of Gastroenterology and Digestive Endoscopy, IRCCS Fondazione Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy.
  • IBD Unit, IRCCS Sacro Cuore Don Calabria Hospital, Negrar di Valpolicella, Italy.

ORCID-Profile: Lorenzo Bertani, Alessia Todeschini

Zitieren

APA

Bertani, L., Ribaldone, D. G., Bossa, F., Guerra, M., Annese, M., Manta, R., Armandi, A., Caviglia, G. P., Todeschini, A., & Variola, A. (2025). When to Switch to Subcutaneous Infliximab? The RE-WATCH Multicenter Study. Inflammatory Bowel Diseases, 31(12), 3363-3369. https://doi.org/10.1093/ibd/izaf172

Vancouver

Bertani L, Ribaldone DG, Bossa F, Guerra M, Annese M, Manta R, et al. When to Switch to Subcutaneous Infliximab? The RE-WATCH Multicenter Study. Inflammatory Bowel Diseases. 2025;31(12):3363-3369. doi:10.1093/ibd/izaf172

BibTeX
@article{Bertani2025,
  author = {Bertani, Lorenzo and Ribaldone, Davide Giuseppe and Bossa, Fabrizio and Guerra, Maria and Annese, Monica and Manta, Raffaele and Armandi, Angelo and Caviglia, Gian Paolo and Todeschini, Alessia and Variola, Angela},
  title = {When to Switch to Subcutaneous Infliximab? The RE-WATCH Multicenter Study},
  journal = {Inflammatory Bowel Diseases},
  year = {2025},
  volume = {31},
  number = {12},
  pages = {3363--3369},
  doi = {10.1093/ibd/izaf172}
}
Kostenlos starten →